Separately, Maxim Group upgraded shares of Atossa Genetics from a “hold” rating to a “buy” rating in a research note on Wednesday, December 18th.
Shares of NASDAQ ATOS opened at $1.57 on Friday. The company has a fifty day moving average price of $1.50 and a 200 day moving average price of $1.85. Atossa Genetics has a 1-year low of $1.19 and a 1-year high of $7.39.
Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings data on Wednesday, November 13th. The company reported ($0.36) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.16.
A hedge fund recently raised its stake in Atossa Genetics stock. Vanguard Group Inc. lifted its holdings in shares of Atossa Genetics Inc (NASDAQ:ATOS) by 73.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 120,689 shares of the company’s stock after buying an additional 51,200 shares during the period. Vanguard Group Inc. owned about 1.32% of Atossa Genetics worth $308,000 at the end of the most recent quarter. Institutional investors and hedge funds own 2.73% of the company’s stock.
About Atossa Genetics
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
Featured Article: What is Forex?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.